Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Davide Busato, Monica Mossenta, Lorena Baboci, Federica Di Cintio, Giuseppe Toffoli & Michele Dal Bo. (2019) Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology 12:5, pages 453-470.
Read now
Read now
Min Li, Weiyue Zhang, Birong Wang, Yang Gao, Zifang Song & Qi Chang Zheng. (2016) Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. International Journal of Nanomedicine 11, pages 5645-5669.
Read now
Read now
Articles from other publishers (62)
Xiaoyu Liu, Qingqing Tan, Jiaqi Wen, Xufei Wang, Gang Yang, Yuxiao Li, Ming Lu, Wei Ye, Anfeng Si, Sujuan Ma, Tong Ding, Luan Sun, Fang Liu, Mei Zhang, Tao Jiang & Wei Gao. (2023) Improving the cytotoxicity of immunotoxins by reducing the affinity of the antibody in acidic pH. Journal of Translational Medicine 21:1.
Crossref
Crossref
Cristina Larrosa, Jaume Mora & Nai-Kong Cheung. (2023) Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2. Cancers 15:14, pages 3729.
Crossref
Crossref
Stanley Fayn, A. Paden King, Nicholas T. Gutsche, Zhijian Duan, Jesse Buffington, Colleen P. Olkowski, Ying Fu, Jessica Hong, Deepak Sail, Kwamena E. Baidoo, Rolf E. Swenson, Ross W. Cheloha, Mitchell Ho, Peter L. Choyke & Freddy E. Escorcia. (2023) Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3–Expressing Liver Cancer by Immuno-PET. Journal of Nuclear Medicine 64:7, pages 1017-1023.
Crossref
Crossref
Nan Li, Alex Quan, Dan Li, Jiajia Pan, Hua Ren, Gerard Hoeltzel, Natalia de Val, Dana Ashworth, Weiming Ni, Jing Zhou, Sean Mackay, Stephen M. Hewitt, Raul Cachau & Mitchell Ho. (2023) The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer. Nature Communications 14:1.
Crossref
Crossref
Antonio Arulanandam, Liang Lin, Hao-Ming Chang, Martine Cerutti, Sylvie Choblet, Peng Gao, Armin Rath, Armand Bensussan, Jean Kadouche, Daniel Teper, Ofer Mandelboim & Wei Li. (2023) Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3. Cells 12:7, pages 996.
Crossref
Crossref
Aarti Kolluri, Dan Li, Nan Li, Zhijian Duan, Lewis R. Roberts & Mitchell Ho. (2023) Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC. Hepatology Communications 7:2, pages e0022-e0022.
Crossref
Crossref
Lichun Ma, Sophia Heinrich, Limin Wang, Friederike L. Keggenhoff, Subreen Khatib, Marshonna Forgues, Michael Kelly, Stephen M. Hewitt, Areeba Saif, Jonathan M. Hernandez, Donna Mabry, Roman Kloeckner, Tim F. Greten, Jittiporn Chaisaingmongkol, Mathuros Ruchirawat, Jens U. Marquardt & Xin Wei Wang. (2022) Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nature Communications 13:1.
Crossref
Crossref
Rui Mao, Wanqing Kong & Yukai He. (2022) The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better. Frontiers in Immunology 13.
Crossref
Crossref
Monica Mossenta, Davide Busato, Michele Dal Bo, Paolo Macor & Giuseppe Toffoli. (2022) Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. International Journal of Molecular Sciences 23:17, pages 10038.
Crossref
Crossref
Leidy D. Caraballo Galva, Xiaotao Jiang, Mohamed S. Hussein, Huajun Zhang, Rui Mao, Pierce Brody, Yibing Peng, Aiwu Ruth He, Mercy Kehinde‐Ige, Ramses Sadek, Xiangguo Qiu, Huidong Shi & Yukai He. (2021) Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC. Hepatology 76:2, pages 330-344.
Crossref
Crossref
Harriet Roddy, Tim Meyer & Claire Roddie. (2022) Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers 14:3, pages 504.
Crossref
Crossref
Xin Chen, Yanmin Chen, Rong Liang, Lanxin Xiang, Jingwen Li, Yuankui Zhu, Huixia He, Le Huang, Dianbao Zuo, Weihang Li, Xinjun Liang, Shuang Dong, Sheng Hu, Mitchell Ho & Mingqian Feng. (2022) Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice. Molecular Cancer Therapeutics 21:1, pages 149-158.
Crossref
Crossref
Dan Li, Shaoli Lin, Jessica Hong & Mitchell Ho. 2022. Hepatobiliary Cancers: Translational Advances and Molecular Medicine. Hepatobiliary Cancers: Translational Advances and Molecular Medicine
415
449
.
Dhatri Madduru, Ngalah Bidii Stephen, Urvashi Vijay, Pranathi Pappu, Prashanth Suravajhala & Obul Reddy Bandapalli. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3
225
243
.
Anita Bakrania, Gang Zheng & Mamatha Bhat. (2021) Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment. Pharmaceutics 14:1, pages 41.
Crossref
Crossref
Jiajia Pan & Mitchell Ho. (2021) Role of glypican-1 in regulating multiple cellular signaling pathways. American Journal of Physiology-Cell Physiology 321:5, pages C846-C858.
Crossref
Crossref
Nan Li, Madeline B. Torres, Madeline R. Spetz, Ruixue Wang, Luyi Peng, Meijie Tian, Christopher M. Dower, Rosa Nguyen, Ming Sun, Chin-Hsien Tai, Natalia de Val, Raul Cachau, Xiaolin Wu, Stephen M. Hewitt, Rosandra N. Kaplan, Javed Khan, Brad St Croix, Carol J. Thiele & Mitchell Ho. (2021) CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice. Cell Reports Medicine 2:6, pages 100297.
Crossref
Crossref
Sheng Yu, Zhenfeng Li, Jingzhang Li, Shimei Zhao, Shanguang Wu, Hongjing Liu, Xiongjie Bi, Dongyang Li, Jiexian Dong, Siliang Duan & Bruce D. Hammock. (2021) Generation of dual functional nanobody-nanoluciferase fusion and its potential in bioluminescence enzyme immunoassay for trace glypican-3 in serum. Sensors and Actuators B: Chemical 336, pages 129717.
Crossref
Crossref
Lin Yu, Xi Yang, Nan Huang, Meng Wu, Heng Sun, Qilin He, Qiaoli Lang, Xiangang Zou, Zuohua Liu, Jianhua Wang & Liangpeng Ge. (2020) Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumors. Investigational New Drugs 39:3, pages 615-626.
Crossref
Crossref
Luan Sun, Fang Gao, Zhanhui Gao, Lei Ao, Na Li, Sujuan Ma, Meng Jia, Nan Li, Peihua Lu, Beicheng Sun, Mitchell Ho, Shaochang Jia, Tong Ding & Wei Gao. (2021) Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. Journal for ImmunoTherapy of Cancer 9:4, pages e001875.
Crossref
Crossref
Lin Yu, Nan Huang, Heng Sun, Xi Yang, Yuna Fu, Qiaoli Lang, Jianhua Wang & Liangpeng Ge. (2021) Development of a Tetravalent T-Cell Engaging Bispecific Antibody Against Glypican-3 for Hepatocellular Carcinoma. Journal of Immunotherapy 44:3, pages 106-113.
Crossref
Crossref
Tanja Gerlza, Christina Trojacher, Nikola Kitic, Tiziana Adage & Andreas J. Kungl. (2021) Development of Molecules Antagonizing Heparan Sulfate Proteoglycans. Seminars in Thrombosis and Hemostasis 47:03, pages 316-332.
Crossref
Crossref
Nan Li, Madeline R. Spetz & Mitchell Ho. (2020) The Role of Glypicans in Cancer Progression and Therapy. Journal of Histochemistry & Cytochemistry 68:12, pages 841-862.
Crossref
Crossref
Xiaoyu Liu, Fang Gao, Longwei Jiang, Meng Jia, Lei Ao, Ming Lu, Liming Gou, Mitchell Ho, Shaochang Jia, Fei Chen & Wei Gao. (2020) 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma. Journal of Translational Medicine 18:1.
Crossref
Crossref
Tsung-Chieh Shih, Lijun Wang, Hsiao-Chi Wang & Yu-Jui Yvonne Wan. (2020) Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma. Liver Research 4:4, pages 168-172.
Crossref
Crossref
Michele Dal Bo, Elena De Mattia, Lorena Baboci, Silvia Mezzalira, Erika Cecchin, Yehuda G. Assaraf & Giuseppe Toffoli. (2020) New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 51, pages 100702.
Crossref
Crossref
David Dahlgren & Hans Lennernäs. (2020) Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules 25:12, pages 2861.
Crossref
Crossref
Bryan D. Fleming & Mitchell Ho. (2020) Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. Biomolecules 10:6, pages 934.
Crossref
Crossref
Dan Li, Nan Li, Yi-Fan Zhang, Haiying Fu, Mingqian Feng, Dina Schneider, Ling Su, Xiaolin Wu, Jing Zhou, Sean Mackay, Josh Kramer, Zhijian Duan, Hongjia Yang, Aarti Kolluri, Alissa M. Hummer, Madeline B. Torres, Hu Zhu, Matthew D. Hall, Xiaoling Luo, Jinqiu Chen, Qun Wang, Daniel Abate-Daga, Boro Dropulic, Stephen M. Hewitt, Rimas J. Orentas, Tim F. Greten & Mitchell Ho. (2020) Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology 158:8, pages 2250-2265.e20.
Crossref
Crossref
Nancy A. Espinoza-Sánchez & Martin Götte. (2020) Role of cell surface proteoglycans in cancer immunotherapy. Seminars in Cancer Biology 62, pages 48-67.
Crossref
Crossref
Bryan D. Fleming, Daniel J. Urban, Matthew D. Hall, Thomas Longerich, Tim F. Greten, Ira Pastan & Mitchell Ho. (2020) Engineered Anti‐GPC3 Immunotoxin, HN3‐ABD‐T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. Hepatology 71:5, pages 1696-1711.
Crossref
Crossref
Ruonan Feng, Ruixue Wang, Jessica Hong, Christopher M Dower, Brad St Croix & Mitchell Ho. (2020) Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display. Antibody Therapeutics 3:1, pages 10-17.
Crossref
Crossref
Rose M. BermanOlivia J. KeladaNicholas T. GutscheRaju NatarajanRolf E. SwensonYing FuJessica HongMitchell HoPeter L. ChoykeFreddy E. Escorcia. (2019)
In Vitro
Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency
. Cancer Biotherapy and Radiopharmaceuticals 34:8, pages 498-503.
Crossref
Crossref
Na Li, Liwen Wei, Xiaoyu Liu, Hongjun Bai, Yvonne Ye, Dan Li, Nan Li, Ulrich Baxa, Qun Wang, Ling Lv, Yun Chen, Mingqian Feng, Byungkook Lee, Wei Gao & Mitchell Ho. (2019) A Frizzled‐Like Cysteine‐Rich Domain in Glypican‐3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice. Hepatology 70:4, pages 1231-1245.
Crossref
Crossref
Ying Fu, Daniel J. Urban, Roger R. Nani, Yi‐Fan Zhang, Nan Li, Haiying Fu, Hamzah Shah, Alexander P. Gorka, Rajarshi Guha, Lu Chen, Matthew D. Hall, Martin J. Schnermann & Mitchell Ho. (2019) Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology 70:2, pages 563-576.
Crossref
Crossref
Ruixue Wang, Qinhuai Lai, Ying Lu, Yan Zhou, Liangze Tang, Yiran Tao, Yuqin Yao, Lin Yu, Yu Liu, Yuxi Wang, Ruirui Zhang, Xiaohua Jiang, Lantu Gou & Jinliang Yang. (2019) Expression of 5T4 extracellular domain fusion protein and preparation of anti-5T4 monoclonal antibody with high affinity and internalization efficiency. Protein Expression and Purification 158, pages 51-58.
Crossref
Crossref
Michael V. Ortiz, Stephen S. Roberts, Julia Glade Bender, Neerav Shukla & Leonard H. Wexler. (2019) Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. Frontiers in Oncology 9.
Crossref
Crossref
Mingqian Feng, Hejiao Bian, Xiaolin Wu, Tianyun Fu, Ying Fu, Jessica Hong, Bryan D Fleming, Martin F Flajnik & Mitchell Ho. (2019) Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naïve nurse sharks. Antibody Therapeutics 2:1, pages 1-11.
Crossref
Crossref
Qi Zhang, Zhihao Han, Ji Tao, Menglu Zhao, Wancun Zhang, Ping Li, Liping Tang & Yueqing Gu. (2019) An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis. Biomaterials Science 7:1, pages 159-167.
Crossref
Crossref
Nan Li, Wei Gao, Yi-Fan Zhang & Mitchell Ho. (2018) Glypicans as Cancer Therapeutic Targets. Trends in Cancer 4:11, pages 741-754.
Crossref
Crossref
Jad Chahoud, Miao Zhang, Louis L. Pisters, Song-Chang Lin, Sue-Hwa Lin & Shi-Ming Tu. (2018) Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clinical Genitourinary Cancer 16:5, pages 325-327.
Crossref
Crossref
Fubo Zhou, Wenting Shang, Xiaoling Yu & Jie Tian. (2018) Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Medicinal Research Reviews 38:2, pages 741-767.
Crossref
Crossref
Jing Fu & Hongyang Wang. (2018) Precision diagnosis and treatment of liver cancer in China. Cancer Letters 412, pages 283-288.
Crossref
Crossref
Cristian Turato, Anna Balasso, Vinicio Carloni, Claudio Tiribelli, Francesca Mastrotto, Antonio Mazzocca & Patrizia Pontisso. (2017) New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. Journal of Controlled Release 268, pages 184-197.
Crossref
Crossref
Arpad Szoor, Abishek Vaidya, Mireya Paulina Velasquez, Zhuyong Mei, Daniel L. Galvan, David Torres, Adrian Gee, Andras Heczey & Stephen Gottschalk. (2017) T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC. Molecular Therapy - Oncolytics 6, pages 69-79.
Crossref
Crossref
Chunguang Wang, Wei Gao, Mingqian Feng, Ira Pastan & Mitchell Ho. (2016) Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. Oncotarget 8:20, pages 32450-32460.
Crossref
Crossref
Wenpeng LiLinjie GuoPurva Rathi, Ekaterina MarinovaXiuhua GaoMeng-Feng Wu, Hao Liu, Gianpietro DottiStephen Gottschalk, Leonid S. Metelitsa & Andras Heczey. (2017) Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Human Gene Therapy 28:5, pages 437-448.
Crossref
Crossref
Nicole H. Trier & Gunnar Houen. 2017.
43
96
.
Yi-Fan Zhang, Jessica Hong & Mitchell Ho. 2017. Immunotherapy of Hepatocellular Carcinoma. Immunotherapy of Hepatocellular Carcinoma
103
119
.
Yi-Fan Zhang & Mitchell Ho. (2016) Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma. Scientific Reports 6:1.
Crossref
Crossref
Bryan Fleming & Mitchell Ho. (2016) Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins 8:10, pages 274.
Crossref
Crossref
Wei Gao, Yongmei Xu, Jian Liu & Mitchell Ho. (2016) Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate. Scientific Reports 6:1.
Crossref
Crossref
Wei Gao, Heungnam Kim & Mitchell Ho. (2015) Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PLOS ONE 10:9, pages e0137664.
Crossref
Crossref
Hirofumi Hanaoka, Tadanobu Nagaya, Kazuhide Sato, Yuko Nakamura, Rira Watanabe, Toshiko Harada, Wei Gao, Mingqian Feng, Yen Phung, Insook Kim, Chang H. Paik, Peter L. Choyke, Mitchell Ho & Hisataka Kobayashi. (2015) Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy. Molecular Pharmaceutics 12:6, pages 2151-2157.
Crossref
Crossref
Yi-Fan Zhang, Yen Phung, Wei Gao, Seiji Kawa, Raffit Hassan, Ira Pastan & Mitchell Ho. (2015) New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma. Scientific Reports 5:1.
Crossref
Crossref
Hirofumi Hanaoka, Takahito Nakajima, Kazuhide Sato, Rira Watanabe, Yen Phung, Wei Gao, Toshiko Harada, Insook Kim, Chang H Paik, Peter L Choyke, Mitchell Ho & Hisataka Kobayashi. (2015) Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine 10:7, pages 1139-1147.
Crossref
Crossref
Wei Gao, Zhewei Tang, Yi-Fan Zhang, Mingqian Feng, Min Qian, Dimiter S. Dimitrov & Mitchell Ho. (2015) Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nature Communications 6:1.
Crossref
Crossref
Huiping Gao, Kesang Li, Hong Tu, Xiaorong Pan, Hua Jiang, Bizhi Shi, Juan Kong, Hongyang Wang, Shengli Yang, Jianren Gu & Zonghai Li. (2014) Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma. Clinical Cancer Research 20:24, pages 6418-6428.
Crossref
Crossref
Wei Gao, Heungnam Kim, Mingqian Feng, Yen Phung, Charles P. Xavier, Jeffrey S. Rubin & Mitchell Ho. (2014) Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology 60:2, pages 576-587.
Crossref
Crossref
Mingqian Feng & Mitchell Ho. (2014) Glypican-3 antibodies: A new therapeutic target for liver cancer. FEBS Letters 588:2, pages 377-382.
Crossref
Crossref
Carlos E. Pedreira, Elaine S. Costa, Quentin Lecrevisse, Jacques J.M. van Dongen & Alberto Orfao. (2013) Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends in Biotechnology 31:7, pages 415-425.
Crossref
Crossref
Mingqian FengWei GaoRuoqi WangWeizao Chen, Yan-Gao Man, William Douglas Figg, Xin Wei WangDimiter S. Dimitrov & Mitchell Ho. (2013) Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proceedings of the National Academy of Sciences 110:12.
Crossref
Crossref